Gábor Somlyai, PhD is a Hungarian molecular biologist and world expert in the role of deuterium in cancer. He has published seminal work looking at the effects of various concentrations of this heavy isotope of hydrogen on growth and metastasis. Gábor’s company, HYD LLC. for Cancer Research and Drug Development, has been at the forefront of developing deuterium depletion protocols as a synergistic cancer therapy. Their work over the last 30+ years has demonstrated the profound potential of deuterium depletion in not only cancer, but other disorders including type 2 diabetes. The identification of this submolecular regulatory system shaped by the relative abundance of deuterium to hydrogen in the body provides a framework with which we can further understand what cancer is and how sensitive our bodies are to subtle environmental information.

All elements on the periodic table have isotopes - slightly different configurations of the same atoms that have slightly different chemical characteristics. Hydrogen is the simplest atom, with one proton, and one electron. But hydrogen also has another stable isotope called deuterium, with one proton, one electron and one neutron. This is still hydrogen, but it is double the atomic weight and consequently behaves differently. In our bodies, approximately 1 out of every 6600 hydrogen atoms (also referred to as 150ppm) is a deuterium atom. Our cells are exquisitely tuned to this deuterium/hydrogen ratio, and they use this ratio as a foundational signal in cell division. As deuterium levels shift, large scale changes in bioenergetics and genetic expression result. Gábor’s work shows that lowering the deuterium level can effectively inhibit the growth of cancer cells.

Gábor's Work

Preventa Deuterium Depleted Water

Follow Me